 |
|
|
|
February 2006 Cover
|
|
Bristol-Myers Squibb Co. (BMS) and Gilead Sciences Inc. (GSI) announced they would apply for Food and Drug Administration approval of a pill combining two AIDS drugs. Using a
bi-layering process, the companies combined BMS' Sustiva and GSI's Truvada in a fixed dose. They found the treatment proved equivalent to taking the drugs separately, thus meeting a
regulatory requirement. The companies said they would apply for FDA approval between April and June.
Editor's Note: from Associated Press
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
